Angion Announces Participation in Upcoming Investment Conference
Angion Biomedica Corp. (NASDAQ:ANGN) announced its participation in the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 AM Eastern Time. President and CEO Dr. Jay Venkatesan will present virtually, and interested parties can access a webcast via Angion's investor website. Angion focuses on developing therapeutics for fibrotic diseases, with its lead candidate, ANG-3070, in a Phase 2 trial targeting kidney diseases. The webcast will be archived for 30 days post-event.
- Participation in H.C. Wainwright Global Investment Conference enhances visibility.
- ANG-3070 is in a Phase 2 clinical trial for primary proteinuric kidney diseases, indicating progress in drug development.
- None.
UNIONDALE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.
Angion’s President and CEO, Dr. Jay Venkatesan, will participate virtually in the H.C. Wainwright Global Investment Conference. Details are as follows:
Event: H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 7:00am Eastern US Time
A webcast of the event will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.
About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in JUNIPER, a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition. For more information, please visit www.angion.com.
FAQ
What is Angion Biomedica's lead product candidate?
When is Angion Biomedica participating in the investment conference?
What is the purpose of the JUNIPER trial?
Where can I watch the webcast of Angion Biomedica's conference participation?
